drugset

drugset / Trial / NCT04571164

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

NCT04571164 ↗

Phase 3 Completed 294 enrolled Luye Pharma Group Ltd. Parexel · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections

Timeline

Start: 2020-05-11
Primary completion: 2022-03-17
Completion: 2022-09-27

Outcome

Met primary endpoint

release “LY03003）治疗帕金森病的中国Ⅲ期临床试验达到预设终点” luye.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY03003	Unknown	56 mg	Intramuscular

Indications